32.1 Composition of platinum‐chromium (PtCr) compared with stainless s...Table 32.2 Mechanical properties of PtCr compared with stainless steel and C...Table 32.3 Summary of clinical trials of Synergy stent.23 Chapter 33Table 33.1 Characteristics of resolute onyx and other contemporary drug‐elut...Table 33.2 Key features of ZES.Table 33.3 Selected all‐comers RCT evaluating ZES.
24 Chapter 34Table 34.1 Overview of clinical studies with the biosensor international bio...Table 34.2 Overview of completed clinical studies with the biosensor interna...Table 34.3 Overview of completed clinical studies with the nobori biolimus‐e...
25 Chapter 35Table 35.1 The orsiro clinical program.Table 35.2 Absorbable magnesium scaffolds.
26 Chapter 36Table 36.1 Main current durable polymer drug‐eluting coronary stent systems....Table 36.2 Main current biodegradable polymer drug‐eluting coronary stent sy...Table 36.3 Main current polymer‐free drug‐eluting coronary stent systems.Table 36.4 Novel durable and biodegradable polymer drug‐eluting coronary ste...
27 Chapter 38Table 38.1 Properties of current and emerging P2Y12 ADP receptor antagonists...Table 38.2 Comparison of pharmacologic properties of current anticoagulants....
28 Chapter 39Table 39.1 Summary of current european guidelines regarding the use of oral ...
29 Chapter 40Table 40.1 Comparison of antithrombotic agents.Table 40.2 Comparison of low molecular weight heparins.Table 40.3 European and US guidelines indications for the use of parenteral ...
30 Chapter 41Table 41.1 Vasodilators used in PCI.Table 41.2 Overview of short‐acting drugs used in peri‐procedural sedation....Table 41.3 Drugs that should be stopped prior to PCI.
31 Chapter 42Table 42.1 ESC Guidelines for the recommended antithrombotic strategies foll...
32 Chapter 43Table 43.1 ARC‐2 definitions of myocardial infarction, stent thrombosis and ...Table 43.2 Features of high ischemic risk in patients undergoing stent impla...Table 43.3 Risk prediction models for ischemic and bleeding events in PCI pa...
33 Chapter 45Table 45.1 Randomized trials of personalized antiplatelet therapy.Table 45.2 Relation between platelet function measurement and bleeding in pa...Table 45.3 Platelet reactivity cut‐off associated with ischemic and bleeding...
34 Chapter 46Table 46.1 Types and properties of common anticoagulant agents.Table 46.2 2017 ACC expert consensus decision pathway on management of bleed...
35 Chapter 47Table 47.1 Physiologic hemodynamic values.Table 47.2 Characterization of various forms of PH.Table 47.3 Infracardiac hemodynamics and shunt calculations.
36 Chapter 48Table 48.1 Novel oral anticoagulants for the treatment of acute venous throm...Table 48.2 Contraindications to systemic thrombolysis.Table 48.3 Peri‐catheter lysis anticoagulation management.
37 Chapter 49Table 49.1 The currently available renal denervation catheters with CE mark....
38 Chapter 50Table 50.1 Summary of main studies evaluating long‐term antiplatelet strateg...Table 50.2 Summary of main studies evaluating long‐term oral anticoagulation...Table 50.3 Current guideline recommendations for antithrombotic strategies a...
39 Chapter 52Table 52.1 How to implant a Watchman device, step by step:
40 Chapter 55Table 55.1 Selected aortic valvuloplasty balloons and recommended sheath siz...Table 55.2 Complications of balloon aortic valvuloplasty.
41 Chapter 56Table 56.1 Dimensional data of the Sapien 3/3 Ultra valve system.Table 56.2 Design features of different iterations of the balloon‐expandable...Table 56.3 Important large‐cohort clinical trials involving the Edwards Sapi...Table 56.4 Relative advantages and disadvantages of the Sapien 3/3 Ultra val...
42 Chapter 57Table 57.1 Aortic Annulus Diameters and Minimum Vessel Sizes for Evolut PRO+...Table 57.2 Aortic annulus diameters and perimeters for ACURATE neo valves.Table 57.3 Aortic annulus diameters and perimeters for portico valves.
43 Chapter 59Table 59.1 Contemporary incidence of paravalvular regurgitation with differe...Table 59.2 Pre‐procedural CT findings associated with elevated risk of speci...Table 59.3 Comparison of two CE marked cerebral embolic protection devices....
44 Chapter 60Table 60.1 Characteristics of high, intermediate and low‐risk patients enrol...Table 60.2 Key data for post TAVR hand‐over.
45 Chapter 62Table 62.1 Pathophysiologic triad.
46 Chapter 63Table 63.1 Complications of transseptal catheterization.
47 Chapter 64.1Table 64.1.1 Morphologic patterns for MitraClip therapy.Table 64.1.2 COAPT‐like profile predictors of favorable long‐term outcomes a...Table 64.1.3 Major differences in baseline characteristics between COAPT and...Table 64.1.4 Novel percutaneous devices for mitral regurgitation repair.
48 Chapter 64.2Table 64.2.1 Clinical and procedural outcomes of transcatheter mitral valve‐...Table 64.2.2 TMVR devices for treatment of native valve mitral regurgitation...Table 64.2.3 Short‐term outcomes of TMVR for native valve mitral regurgitati...
49 Chapter 65Table 65.1 Echocardiography scoring system (Wilkins score) to predict outcom...Table 65.2 Complications during balloon mitral valvuloplasty.
50 Chapter 67Table 67.1 Proposed Indications for PVR [49].
51 Chapter 69Table 69.1 Overview of mechanical support devices.
52 Chapter 70Table 70.1 Procedural steps for CardioMEMS implant.
53 Chapter 71Table 71.1 Contraindications to systemic lytic therapy.
54 Chapter 72Table 72.1 Comparison of landmark carotid stenting trials.Table 72.2 Comparison of embolic protection modalities.
55 Chapter 74Table 74.1 Morbidity and Mortality for Open and Endovascular Treatment of Ac...Table 74.2 Predictors of Intramural Hematoma Complications.
56 Chapter 75Table 75.1 High risk features.Table 75.2 TEVAR devices.Table 75.3 Protective measures to prevent spinal cord ischemia.Table 75.4 Risk factors for SCI.
57 Chapter 77Table 77.1 Cook Zenith fenestrated graft indications for use.
58 Chapter 79Table 79.1 Diagnosis criteria of renal artery stenosis by duplex ultrasound....
59 Chapter 80Table 80.1 Endovascular treatment of erectile dysfunction.
60 Chapter 82Table 82.1 Alternate Access for SFA Interventions.Table 82.2 Atherectomy devices.Table 82.3 Drug Coated Technologies.
61 Chapter 84Table 84.1 Rutherford classification of peripheral artery disease and critic...Table 84.2 Options for interventional treatment of lower extremity arterial ...
62 Chapter 86Table 86.1 Risk of bleeding among the two treatment arms in the CHARISMA tri...
63 Chapter 87Table 87.1 CEAP classification for chronic venous disorders.Table 87.2 Revised venous clinical severity score.
List of Illustrations
1 Chapter 1Figure 1.1 OCT illustration of Neoatherosclerosis. (a) Neo‐intimal hyperplas...Figure
